COMPANY PROFILE · UPDATED 18 NOV 2025

ROME Therapeutics

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug…

rometx.com ↗

This profile is unclaimed — do you work here? Claim it

Claim it →

Founded: 2020
Headcount: 67
Open roles: 0
Last raised: Series B · Sign in to view

LEADERSHIP

Founders & key people

Rosana Kapeller

CEO at ROME Therapeutics

ROME TherapeuticsGVNimbus DiscoveryAileron TherapeuticsAtlas VentureCedilla TherapeuticsUERJTufts University

Benjamin Greenbaum

Founder at ROME Therapeutics

ROME TherapeuticsIcahn School of Medicine at Mount Sinai

David Ting

CTO at Zenni Optical

PanTher TherapeuticsROME TherapeuticsTellBioHarvard Medical SchoolMGH Center for Innovation in Digital HealthCare (CIDH)Harvard Medical School and Massachusetts General HospitalHarvard Medical SchoolMassachusetts Institute of Technology (MIT)Duke University School of MedicineDuke University

Jay Parrish

CEO at Pretzel Therapeutics

Arch Venture PartnersInterline TherapeuticsPretzel TherapeuticsROME TherapeuticsLilac TherapeuticsOrbital TherapeuticsChamberlain Senior High SchoolHaas School of BusinessUniversity of California BerkeleyUniversity of South Florida

David Ting

Rosana Kapeller-Libermann

OPEN ROLES

Roles at ROME Therapeutics

Employbl doesn’t track ROME Therapeutics’s job board yet, so there’s nothing to show here — they may still be hiring. You can also search all jobs →

FUNDING

Capital raised

Total raised

$199,000,000

Investors

Gv Andreessen HorowitzAlexandria Venture InvestmentsArch Venture PartnersArchVenturesAxon VenturesBristol-Myers Squibb CompanyCasdin CapitalEurofarma VenturesJohnson & Johnson InnovationLuma GroupMass General BrighamMirae Asset CapitalPartners Innovation FundRS ParticipatiesS32SanofiSigmas Group

Funding rounds

Series B
Alexandria Venture Investments, Sigmas Group, Johnson & Johnson Innovation, ArchVentures, Bristol-Myers Squibb Company, Andreessen Horowitz, Axon Ventures, Mirae Asset Capital, Sanofi, S32, Casdin Capital, Mass General Brigham, Luma Group, GV, RS Participaties, Eurofarma Ventures
$72MSep 11, 2023
Series B
S32, Sanofi, Alexandria Venture Investments, GV, Arch Venture Partners, Casdin Capital, Andreessen Horowitz, Mass General Brigham
$77MSep 13, 2021
Series A
GV, Partners Innovation Fund, Arch Venture Partners
$50MApr 26, 2020